France · Delayed Price · Currency is EUR bioMérieux Statistics
Total Valuation
bioMérieux has a market cap or net worth of EUR 8.48 billion. The enterprise value is 8.24 billion.
| Market Cap | 8.48B |
| Enterprise Value | 8.24B |
Important Dates
The last earnings date was Tuesday, July 28, 2026.
| Earnings Date | Jul 28, 2026 |
| Ex-Dividend Date | Jun 9, 2026 |
Share Statistics
bioMérieux has 117.95 million shares outstanding. The number of shares has decreased by -0.30% in one year.
| Current Share Class | 117.95M |
| Shares Outstanding | 117.95M |
| Shares Change (YoY) | -0.30% |
| Shares Change (QoQ) | -0.34% |
| Owned by Insiders (%) | 0.05% |
| Owned by Institutions (%) | 17.80% |
| Float | 40.29M |
Valuation Ratios
The trailing PE ratio is 18.42 and the forward PE ratio is 15.95. bioMérieux's PEG ratio is 4.76.
| PE Ratio | 18.42 |
| Forward PE | 15.95 |
| PS Ratio | 2.12 |
| PB Ratio | 1.97 |
| P/TBV Ratio | 2.71 |
| P/FCF Ratio | 14.54 |
| P/OCF Ratio | 9.36 |
| PEG Ratio | 4.76 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 7.72, with an EV/FCF ratio of 14.14.
| EV / Earnings | 17.81 |
| EV / Sales | 2.07 |
| EV / EBITDA | 7.72 |
| EV / EBIT | 13.47 |
| EV / FCF | 14.14 |
Financial Position
The company has a current ratio of 2.30, with a Debt / Equity ratio of 0.10.
| Current Ratio | 2.30 |
| Quick Ratio | 1.44 |
| Debt / Equity | 0.10 |
| Debt / EBITDA | 0.40 |
| Debt / FCF | 0.72 |
| Interest Coverage | 38.72 |
Financial Efficiency
Return on equity (ROE) is 11.22% and return on invested capital (ROIC) is 14.71%.
| Return on Equity (ROE) | 11.22% |
| Return on Assets (ROA) | 8.88% |
| Return on Invested Capital (ROIC) | 14.71% |
| Return on Capital Employed (ROCE) | 13.40% |
| Weighted Average Cost of Capital (WACC) | 7.18% |
| Revenue Per Employee | 267,933 |
| Profits Per Employee | 31,059 |
| Employee Count | 15,226 |
| Asset Turnover | 0.72 |
| Inventory Turnover | 1.80 |
Taxes
In the past 12 months, bioMérieux has paid 145.00 million in taxes.
| Income Tax | 145.00M |
| Effective Tax Rate | 23.88% |
Stock Price Statistics
The stock price has decreased by -42.58% in the last 52 weeks. The beta is 0.57, so bioMérieux's price volatility has been lower than the market average.
| Beta (5Y) | 0.57 |
| 52-Week Price Change | -42.58% |
| 50-Day Moving Average | 70.61 |
| 200-Day Moving Average | 90.79 |
| Relative Strength Index (RSI) | 51.43 |
| Average Volume (20 Days) | 181,465 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, bioMérieux had revenue of EUR 3.99 billion and earned 462.60 million in profits. Earnings per share was 3.90.
| Revenue | 3.99B |
| Gross Profit | 2.24B |
| Operating Income | 785.30M |
| Pretax Income | 607.10M |
| Net Income | 462.60M |
| EBITDA | 1.07B |
| EBIT | 611.80M |
| Earnings Per Share (EPS) | 3.90 |
Balance Sheet
The company has 657.70 million in cash and 421.80 million in debt, with a net cash position of 235.90 million or 2.00 per share.
| Cash & Cash Equivalents | 657.70M |
| Total Debt | 421.80M |
| Net Cash | 235.90M |
| Net Cash Per Share | 2.00 |
| Equity (Book Value) | 4.30B |
| Book Value Per Share | 36.49 |
| Working Capital | 1.47B |
Cash Flow
In the last 12 months, operating cash flow was 905.10 million and capital expenditures -322.10 million, giving a free cash flow of 583.00 million.
| Operating Cash Flow | 905.10M |
| Capital Expenditures | -322.10M |
| Depreciation & Amortization | 289.60M |
| Net Borrowing | -106.80M |
| Free Cash Flow | 583.00M |
| FCF Per Share | 4.94 |
Margins
Gross margin is 56.13%, with operating and profit margins of 19.68% and 11.59%.
| Gross Margin | 56.13% |
| Operating Margin | 19.68% |
| Pretax Margin | 15.21% |
| Profit Margin | 11.59% |
| EBITDA Margin | 26.74% |
| EBIT Margin | 15.33% |
| FCF Margin | 14.61% |
Dividends & Yields
This stock pays an annual dividend of 0.98, which amounts to a dividend yield of 1.35%.
| Dividend Per Share | 0.98 |
| Dividend Yield | 1.35% |
| Dividend Growth (YoY) | 8.89% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 24.90% |
| Buyback Yield | 0.30% |
| Shareholder Yield | 1.64% |
| Earnings Yield | 5.46% |
| FCF Yield | 6.88% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for bioMérieux is 79.04, which is 10.39% higher than the current price. The consensus rating is "Hold".
| Price Target | 79.04 |
| Price Target Difference | 10.39% |
| Analyst Consensus | Hold |
| Analyst Count | 14 |
| Revenue Growth Forecast (3Y) | 4.02% |
| EPS Growth Forecast (3Y) | 2.93% |
Stock Splits
The last stock split was on September 20, 2017. It was a forward split with a ratio of 3.
| Last Split Date | Sep 20, 2017 |
| Split Type | Forward |
| Split Ratio | 3 |
Scores
bioMérieux has an Altman Z-Score of 6.66 and a Piotroski F-Score of 6.
| Altman Z-Score | 6.66 |
| Piotroski F-Score | 6 |